Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.56 - $14.45
Previous CloseN/A
Volume25.73M
Average Volume (3M)2.87M
Market Cap
$1.35B
Enterprise Value$132.28M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Feb 26, 2025EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding137,720,120
10 Day Avg. Volume1,023,892
30 Day Avg. Volume2,870,778
Standard Deviation0.27
R-Squared0.01
Alpha0.00512
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.16
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$31.38Price Target Upside227.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Vir Biotechnology News
PremiumCompany Announcements
Vir Biotechnology Announces Leadership Change in 2025
PremiumCompany Announcements
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
---
Bulls Say, Bears Say
Bulls Say
Oncology ProgressVir's dual-masking T-cell engager platform has shown positive initial efficacy and safety data, which supports a positive outlook for the company's progress in oncology.
Regulatory AdvantagesVir's HDV program has received multiple favorable regulatory designations, providing external validation and facilitating future regulatory interactions.
Strategic AcquisitionThe strategic acquisition of the PRO-XTEN platform provides synergies and differentiation in oncology and infectious diseases.
Bears Say
Investor ConcernsThe HER2 and PSMA programs have sizable patient numbers in the reported datasets, which helps alleviate prior investor questions and debates.
Market Execution RisksThere is significant upside potential from current stock levels as Vir executes on its refined strategy.
Safety Profile ChallengesPh.1 HER2 and PSMA TCE data showed compelling safety differentiation in larger-than-expected evaluated patient populations, with significantly lower cytokine release syndrome rates compared to competitors.
---
Ownership Overview
13.77% Insiders
13.16% Mutual Funds
22.30% Other Institutional Investors
29.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $6.56 and its highest was $14.45 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.35B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Feb 26, 2025 which is in 3 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Oct 31, 2024. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.052 by -$0.508.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.87.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 137,720,120 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.052. Following the earnings report the stock price went up 23.632%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
---
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.38 (227.90% Upside)
$31.38 (227.90% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $122.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.34%
12-Months-Change
Fundamentals
Return on Equity
-36.58%
Trailing 12-Months
Asset Growth
-26.73%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
---
VIR Company Deck
---
VIR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant strategic achievements such as the licensing agreement with Sanofi and promising clinical trial results in the hepatitis delta program, which were somewhat offset by increased R&D expenses and decreased cash reserves due to the Sanofi transaction. Overall, the company's strategic moves suggest a strong potential for growth in the future.Read More>---
VIR Stock 12 Month Forecast
Average Price Target
$31.38
▲(227.90% Upside)
Technical Analysis
Best Analysts Covering VIR
1 Year
---